SAVE NOW with 10% off all Recombinant Antibodies Shop Now

Aviva & Quantum Announce Partnership

View All News

Quantum-Si and Aviva Systems Biology Partner to Co-Develop Sample Preparation Kits for Protein Sequencing

January 9, 2023

Protein Enrichment Kits to Enable Deep Interrogation of Proteoforms through Protein Sequencing

GUILFORD, Conn.--(BUSINESS WIRE)--Jan. 9, 2023-- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it entered into a partnership with Aviva Systems Biology, a leading provider of antibody, protein, and immunoassay reagent products with an extensive portfolio of over 20,000 antibodies against more than 15,000 human gene targets. This partnership seeks to co-develop protein enrichment kits to enable deep interrogation of proteins of interest and their variants (proteoforms) through protein sequencing.

The co-developed products will include immunoprecipitation kits that fit into existing research workflows to conveniently enrich target proteins prior to amino acid mutation or post-translational modification (PTM) analysis with Quantum-Si’s PlatinumTM protein sequencing platform. This allows researchers to more efficiently and effectively uncover changes in proteins of interest and connect those changes to biological processes and disease.

"Biological processes, disease and health are ultimately attributed to protein function or dysfunction, and protein sequencing can support a greater understanding of these processes by unlocking biological insights at an unprecedented scale," said Jeff Hawkins, CEO of Quantum-Si. "We are committed to enabling existing research workflows with simple convenient solutions for proteomics research, and our partnership with Aviva Systems Biology will enable customers to conduct proteoform analysis in a simple and reproducible manner."

"This partnership brings together unique capabilities from Quantium-Si and Aviva Systems Biology that will accelerate new discoveries in protein research," said Kevin Harvey, President of Aviva. "Speeding up new discoveries is a shared goal at Quantum-Si and Aviva Systems Biology, and we are excited to partner with Quantum-Si to drive proteomics research forward."

About Quantum-Si Incorporated

Quantum-Si, The Protein Sequencing CompanyTM, is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at

About Aviva Systems Biology

Aviva Systems Biology, founded in 2002, is a global market leader in proteomics research offering a broad portfolio of polyclonal and monoclonal antibodies, immunoassay kits, recombinant proteins, and custom protein expression and manufacturing services for academic and biopharma researchers. Headquartered in San Diego, California, Aviva’s offering supports multiple applications including western blotting, IHC, ELISA, and immunoprecipitation along with providing researchers one of the largest catalogs of targets and species to choose from. Learn more at

Forward Looking Statements

This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and development and commercialization of products and services. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's Class A common stock on The Nasdaq Stock Market; the ability to recognize the benefits of the business combination, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; the Company’s ongoing leadership transition; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product development and commercialization activities; the potential attributes and benefits of the Company's products and services; the Company's ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing lease, license, manufacture and supply agreements; the Company's ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that the Company is developing; the size and growth potential of the markets for the Company's future products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's products and services following commercial launch; the Company's estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties described under "Risk Factors" in the Company’s Annual Report for the fiscal year ended December 31, 2021, and in the Company's other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

Source: Aviva Systems Biology